% IMPORTANT: The following is UTF-8 encoded. This means that in the presence % of non-ASCII characters, it will not work with BibTeX 0.99 or older. % Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or % “biber”. @ARTICLE{Chen:169289, author = {L.-J. Chen$^*$ and K. Trares$^*$ and D. C. Laetsch$^*$ and T. N. M. Nguyen$^*$ and H. Brenner$^*$ and B. Schöttker$^*$}, title = {{S}ystematic {R}eview and {M}eta-{A}nalysis on the {A}ssociations of {P}olypharmacy and {P}otentially {I}nappropriate {M}edication {W}ith {A}dverse {O}utcomes in {O}lder {C}ancer {P}atients.}, journal = {The journals of gerontology / A}, volume = {76}, number = {6}, issn = {1758-535X}, address = {Oxford [u.a.]}, publisher = {Oxford Univ. Pr.}, reportid = {DKFZ-2021-01386}, pages = {1044 - 1052}, year = {2021}, note = {C070#LA:C070#}, abstract = {Both polypharmacy and potentially inappropriate medication (PIM) intake are highly prevailing in older cancer patients. However, only studies on the association of polypharmacy and postoperative complications have been meta-analyzed previously.A systematic review and a meta-analysis of prospective/retrospective observational studies reporting associations of polypharmacy or PIM with at least one out of five predefined adverse health outcomes in a population of older cancer patients (≥60 years) were carried out. PubMed and Web of Science were used to search for relevant studies published between January 1991 and March 2020. Data were pooled by adopting a random-effects model.Overall, 42 publications were included in the systematic review. Meta-analyses could be performed on 39 studies about polypharmacy and 13 studies about PIM. Polypharmacy was found to be statistically significantly associated with all-cause mortality (risk ratio $[95\%$ confidence interval]: 1.37 [1.25-1.50]), hospitalization (1.53 [1.37-1.71]), treatment-related toxicity (1.22 [1.01-1.47]), and postoperative complications (1.73 [1.36-2.20]). The association of polypharmacy with prolongation of hospitalization was not statistically significant at the p < .05 significance level (1.62 [0.98-2.66]). With respect to PIM, a statistically significant association with all-cause mortality (1.43 [1.08-1.88]) was observed but not with other adverse outcomes.Polypharmacy was found to be associated with several adverse outcomes and PIM use with all-cause mortality in older cancer patients. However, these results should be interpreted with caution because about three-quarters of the studies identified did not adjust for comorbidity and are prone to confounding by indication.}, subtyp = {Review Article}, keywords = {Adverse drug reaction (Other) / Geriatric oncology (Other) / Hospitalizations (Other) / Mortality (Other) / Postoperative complications (Other)}, cin = {C070}, ddc = {570}, cid = {I:(DE-He78)C070-20160331}, pnm = {313 - Krebsrisikofaktoren und Prävention (POF4-313)}, pid = {G:(DE-HGF)POF4-313}, typ = {PUB:(DE-HGF)16}, pubmed = {pmid:32459845}, doi = {10.1093/gerona/glaa128}, url = {https://inrepo02.dkfz.de/record/169289}, }